Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FHNS8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $15,792
Award facts
- Contract value 100% obligated
- $15,792.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $15,792.20 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of XOLAIR 150 mg/ml syringes. The award, issued on December 19, 2025, with an ultimate completion date of January 13, 2026, utilizes firm fixed-price pricing and carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc. will serve as the sole performer on this delivery order, with no identified subcontractor relationships.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA, designated SPE2DR under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The underlying master contract, awarded on November 13, 2025, carries a $499.999 billion ceiling and extends through December 31, 2036, positioning DMS Pharmaceutical Group as a critical regional pharmaceutical supplier for Department of Defense healthcare operations worldwide. The PPV-G GEN V program represents part of the broader $30.3 billion acquisition strategy designed to support recurring medical supply needs across military healthcare facilities globally, with this specific delivery order addressing immunological therapeutic requirements for DoD medical operations.
Quick answers
Who was awarded contract SPE2DR26FHNS8?
SPE2DR26FHNS8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 19, 2025.
How much is contract SPE2DR26FHNS8 worth?
The government has obligated $15,792 on SPE2DR26FHNS8.
Is contract SPE2DR26FHNS8 an order under another contract?
Yes. SPE2DR26FHNS8 is a delivery order under SPE2DR25D9231, an indefinite delivery contract.
Was contract SPE2DR26FHNS8 competed?
The extent of competition for SPE2DR26FHNS8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award